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Original Paper 
Breast cancer is the most frequent cancer and 
second most common cause of cancer related 
death in women worldwide (1). Although breast 
cancer is not a lethal cancer by self, metastasis to 
distant organs is the main cause of breast cancer 
mortality and is associated with poor prognosis in 
breast cancer patients (2-4). 
Spreading of tumor to auxiliary lymph node is one 
of the most important factors predicting metastasis 
of tumor cells (5, 6). Conventional therapeutic 
strategies includes  assessment of local lymph node  
Breast cancer as a heterogeneous sophisticated disease includes several group 
with discrete clinical consequences. The disease is the most prevalent 
malignancy after non-melanoma skin cancers and it is also considered as the 
second leading cause of death after lung cancer. In fact, breast cancer is 
account for 23% of all cancer cases and 14% of deaths from cancer. The 
major cause of breast cancer deaths is actually metastasis of the tumor. As a 
result, it is prominent to identify the disease mechanism and diagnose 
molecular tools in order to predict metastasis. The specimens were collected 
from 30 metastatic and 30 primary tumor tissues of breast cancer patients. 
After that, RNA extraction was accomplished by means of GeneAll kit and 
then was stored in -80 degrees. Then, cDNA synthesis was carried out by 
miscript II RT kit from Qiagenecompany. Finally, sybergreen Real Time 
PCR of all samples was done for miRNA124, miRNA130a and miRNA 16 as 
a reference by means of Pre-designed primers of Qiagene Company. The 
results of molecular expression study showed that the amount of miRNA 124 
in metastatic tissues has approximately increased double of primary tumor 
tissues. It is also revealed that the amount of miRNA has similarly increased 
by about 1.7 times. According to recent results, it can be possible to regard 
molecule as a major cause of metastasis process in breast cancer. 
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 involvement by neoplastic cells. This helps to 
determining of cancer stage, prognosis and survival 
of patients (7). So, understanding of molecular 
mechanisms underlying metastasis of breast cancer 
has a vital importance to prevention, early diagnosis 
and also improving of therapeutic strategies (2, 7). 
Furthermore, during metastatic cell colonization in 
destination organ some cancerous phenotypes of 
cancer cells reverse to make possible metastatic cells 
colonization (6). Recent fast growing number of 
evidence has supported the role of miRNAs as an 
important contributor to many human complex 
diseases including breast cancer (1, 8). 
In last decade studies have shown that MicroRNA 
expression signature abnormalities are 
associated with tumor initiation, 
development, progression, invasion, metastasis and 
response to therapy (9, 10). Therefore these 
molecules can be used as diagnostic, prognostic and 
also predictive biomarkers (10-12). MicroRNAs 
(miRNAs) are short non-coding RNAs of 21–25 
nucleotides that regulate gene expression post-
transcriptionally by binding to the 3′ untranslated 
region (UTR) of target mRNAs (13, 14). 
Several studies have shown that miRNA expression 
profiling can discriminate between normal breast 
tissue and breast cancer (14). Furthermore 
evaluating of miRNAs profile can predict occurrence 
of tumor metastasis.  These studies suggest potential 
applications for certain miRNAs as 
biomarkers for breast cancer metastasis (2, 10). 
MicroRNA-124 is one of the interesting research 
topics in cancer development and prognosis in 
several cancers. This MicroRNA is known as a 
tumor suppressor in several cancers including breast 
cancer (15). cellular models show that increasing of 
this microRNA is associated with increasing of cell 
motility and invasion of tumor cells. 
However, there is no information about microRNA-
124 expression change during metastasis process. 
Decoding of these changes may help better 
understanding of process of metastatic cell invasion 
and also colonization in destination organ. 
To further investigation of these processes, in this 
experiment we compared the expression levels of 
miRNA-124 in primary breast cancer tissues and 
metastatic tumors.  
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Methods 
Tissue sampling 
Thirty fresh breast tumor tissue, and 30 tumor cell 
bearing lymph node samples were gathered from 
pastor-no and Qaem hospital of Mashhad, Iran. This 
study design was approved by local ethics 
committee of Mashhad University of medical 
sciences and all of patients signed informed consent. 
None of patients recruited in this study had 
undergone preoperative chemotherapy or 
radiotherapy. Identity of tissue samples were 
confirmed by pathologist. Samples were snapped 
frozen and stored in -80°C until use. 
RNA extraction and quantitative real-time PCR 
miRNAs from tissue samples was extracted using 
Hybrid-R miRNA isolation Kit (GeneAll, South 
Korea) according to the manufacturer’s instructions. 
Then, cDNA synthesis was carried out with 
miscript II RT kit (Qiagen, Germany) following the 
manufacturer’s protocol. Quantitative RT-PCR was 
performed using sybergreen based miScript 
Precursor Assays kit (Qiagen, Germany) and Prime 
Q-Master mix (Amplicon, Denmark) in a StepOne 
Real-time PCR system. MIR-16 was used as 
endogenous reference gene and expression changes 
were calculated using DDCt method. 
Statistical analysis 
Independent T test was performed to investigate 
significant difference in MIR-124 expression levels 
between primary breast tumor samples and 
metastatic tissues. P<0.5 was defined as significant 
frequency difference between the two groups. 
 
Result 
To investigate the expressional behavior of miR-
124in human breast cancer metastasis we compared 
miR-124 expression level between breast cancer 
tumors and metastatic lymph nodes from 60 patients. 
Quantitative real-time PCR analysis showed that 
miR-124 expression increase in metastatic lymph 
nodes specimens in compare with primary breast 
tumor tissues (Figure 1). 
 
Discussion 
Breast cancer metastasis to distant organs is a very 
complicated process that significantly reduces 
survival rate of breast cancer patients (2, 7). Fully 
characterization of metastasis process has a vital 
importance to prevention of this process (2, 16).  
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Figure 1: The expression of miR-124 was determined by quantitative real-time PCR (60 metastatic breast cancer and tumor tissues) 
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Conclusions 
Surprisingly, our results obtained by comparing of miR-124 expression level in primary breast cancer cells 
and metastatic cells show increasing of miR-124 expression level in lymph node metastasis samples versus 
primary tumors. 
In conclusion this results suggest that miR-124 can be an important player in orchestrate of metastasis. 
Colonization of metastatic calls into target tissues 
has a reverse order of biologic steps involving in 
metastasis. Mesenchymal to epithelial transition is 
one of the most important steps in implantation of 
metastatic cells into target organs. This process 
includes the transition from motile, multipolar or 
spindle-shaped mesenchymal cells to planar arrays 
of polarized cells called epithelial. Inhibiting of this 
process can help to control of tumor metastasis as a 
therapeutic strategy in treatment of breast cancer.  
Several pathways contribute in MET process which 
can be candidate as therapeutic target (17-19). 
MicroRNA-124 is a relatively known tumor 
suppressor microRNA which represses tumor 
growth, invasion and metastasis. microRNA-124 
reduces Breast cancer epithelial to mesenchymal 
transition (EMT) via targeting of Slug gene (20). 
Furthermore, this microRNA targets TNF-α and 
inhibits EMT in prostate cancer cells (21). 
miR-124 down regulation in breast cancer cell lines 
leads to increase of migration and invasion of cells. 
Furthermore reduction of miR-124 in primary breast 
tumor tissues is associated with increase of tumor 
metastasis (18, 22). 
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